Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill shows promise for Hard-to-Treat cancers

NCT ID NCT05287399

First seen Jan 08, 2026 · Last updated Jun 19, 2026 · Updated 27 times

Summary

This early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor response, but this is a very early step to see if the drug is safe enough for further testing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • California Cancer Associates for Research & Excellence (cCARE)

    Encinitas, California, 92024, United States

  • California Cancer Associates for Research & Excellence (cCARE)

    Fresno, California, 93720, United States

  • California Cancer Associates for Research & Excellence (cCARE)

    San Marcos, California, 92069, United States

  • Nebraska Cancer Specialists

    Omaha, Nebraska, 68130, United States

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.